CLOV · Insider Trading
Clover Health Investments, Corp
Every open-market purchase and sale reported by CLOV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Karen Soares | Chief Legal Officer | Sell | −19,275 | −$89.82K |
| 2026-10-20 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −4,066 | −$17.93K |
| 2026-10-19 | Karen Soares | Chief Legal Officer | Sell | −14,673 | −$68.67K |
| 2026-10-19 | Andrew Toy | Chief Executive Officer | Sell | −62,176 | −$290.98K |
| 2026-10-19 | Joseph Clay Thornton | Interim CFO | Sell | −4,591 | −$21.49K |
| 2026-10-19 | Conrad Wai | CEO, Counterpart Health | Sell | −23,627 | −$110.57K |
| 2026-10-19 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −18,273 | −$85.52K |
| 2026-10-07 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −2,006 | −$9.29K |
| 2026-10-05 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −8,750 | −$38.67K |
| 2026-10-02 | Robert G Torricelli | Director | A | +12,481 | — |
| 2026-10-02 | Andrew Toy | Chief Executive Officer | Sell | −318,806 | −$1.34M |
| 2026-10-02 | Brian James Miller | Director | A | +12,481 | — |
| 2026-09-18 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −1,921 | −$8.76K |
| 2026-09-17 | Joseph Frank Oldakowski | VP OF FINANCE AND CONTROLLER | Sell | −3,170 | −$14.71K |
| 2026-09-16 | Conrad Wai | CEO, Counterpart Health | Sell | −300,000 | −$1.42M |
| 2026-09-15 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −9,273 | −$44.32K |
| 2026-09-15 | Karen Soares | Chief Legal Officer | Sell | −6,846 | −$32.72K |
| 2026-09-14 | Joseph Frank Oldakowski | VP OF FINANCE AND CONTROLLER | Sell | −20,000 | −$103.20K |
| 2026-08-17 | Joseph Clay Thornton | Interim CFO | Sell | −17,775 | −$78.03K |
| 2026-08-13 | Joseph Clay Thornton | Interim CFO | A | +54,347 | — |
| 2026-08-13 | Karen Soares | Chief Legal Officer | A | +108,695 | — |
| 2026-08-10 | Andrew Toy | Chief Executive Officer | Sell | −87,798 | −$408.26K |
| 2026-07-20 | Karen Soares | Chief Legal Officer | Sell | −51,700 | −$233.17K |
| 2026-07-17 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −4,839 | −$21.92K |
| 2026-07-16 | Conrad Wai | CEO, Counterpart Health | Sell | −24,215 | −$113.08K |
| 2026-07-16 | Karen Soares | Chief Legal Officer | Sell | −10,519 | −$49.12K |
| 2026-07-16 | Andrew Toy | Chief Executive Officer | Sell | −62,711 | −$292.86K |
| 2026-07-16 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −13,119 | −$61.27K |
| 2026-07-16 | Joseph Clay Thornton | Interim CFO | Sell | −4,630 | −$21.62K |
| 2026-07-09 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −2,384 | −$11.16K |
| 2026-07-06 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −6,229 | −$32.76K |
| 2026-07-01 | Andrew Toy | Chief Executive Officer | Sell | −313,476 | −$1.67M |
| 2026-06-18 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −2,360 | −$11.28K |
| 2026-06-17 | Joseph Frank Oldakowski | VP OF FINANCE AND CONTROLLER | Sell | −12,102 | −$58.82K |
| 2026-06-16 | Karen Soares | Chief Legal Officer | Sell | −4,681 | −$21.58K |
| 2026-06-16 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −6,350 | −$29.27K |
| 2026-06-11 | Jamie L. Reynoso | CEO, Medicare Advantage | Sell | −7,289 | −$35.79K |
| 2026-05-28 | Conrad Wai | CEO, Counterpart Health | Sell | −220,426 | −$879.50K |
| 2026-05-19 | Carladenise Armbrister Edwards | Director | Sell | −67,160 | −$229.69K |
| 2026-05-18 | Joseph Clay Thornton | Interim CFO | F | −16,942 | −$58.79K |
| 2026-05-13 | Brady Patrick Priest | CEO of Clover Care Services | Sell | −98,039 | −$345.10K |
| 2026-05-12 | Andrew Toy | Chief Executive Officer | F | −85,704 | −$241.69K |
| 2026-04-21 | Brady Patrick Priest | CEO of Clover Care Services | F | −36,113 | −$79.09K |
| 2026-04-16 | Jamie L. Reynoso | CEO, Medicare Advantage | F | −12,712 | −$25.93K |
| 2026-04-16 | Karen Soares | Chief Legal Officer | F | −10,161 | −$20.73K |
| 2026-04-16 | Conrad Wai | CEO, Counterpart Health | F | −23,463 | −$47.86K |
| 2026-04-16 | Joseph Clay Thornton | Interim CFO | F | −4,158 | −$8.48K |
| 2026-04-16 | Andrew Toy | Chief Executive Officer | F | −60,765 | −$123.96K |
| 2026-04-16 | Brady Patrick Priest | CEO of Clover Care Services | F | −15,471 | −$31.56K |
| 2026-04-07 | Jamie L. Reynoso | CEO, Medicare Advantage | F | −6,197 | −$10.66K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Andrew Toy | Chief Executive Officer | 9,078,334 | $42.80M |
| Peter J. Kuipers | Chief Financial Officer | 5,758,353 | $27.15M |
| Vivek Garipalli | Director | 3,512,196 | $16.56M |
| Jamie L. Reynoso | CEO, Medicare Advantage | 2,770,351 | $13.06M |
| Conrad Wai | CEO, Counterpart Health | 2,212,128 | $10.43M |
| Brady Patrick Priest | CEO of Clover Care Services | 2,040,222 | $9.62M |
| Karen Soares | Chief Legal Officer | 1,573,423 | $7.42M |
| Joseph Clay Thornton | Interim CFO | 1,244,935 | $5.87M |
| Demetrios L. Kouzoukas | Director | 605,980 | $2.86M |
| Chelsea Clinton | Director | 602,814 | $2.84M |
| Lee Shapiro | Director | 598,622 | $2.82M |
| William G Robinson Jr | Director | 597,987 | $2.82M |
| Anna U Loengard | Director | 557,066 | $2.63M |
| Carladenise Armbrister Edwards | Director | 285,432 | $1.35M |
| Joseph Frank Oldakowski | VP OF FINANCE AND CONTROLLER | 275,897 | $1.30M |
| Robert G Torricelli | Director | 186,897 | $881.22K |
| Thomas L Tran | Director | 180,029 | $848.84K |
| Brian James Miller | Director | 12,481 | $58.85K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CLOV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.